1
EXHIBIT 10.14
Certain confidential information has been omitted from this Exhibit 10.14
pursuant to a confidential treatment request filed separately with the
Securities and Exchange Commission. The omitted information is indicated by the
symbol "***" at each place in this Exhibit 10.14 where the omitted information
appeared in the original.
MASTER DEVELOPMENT, PURCHASING AND LICENSE AGREEMENT
BETWEEN
INTEL CORPORATION AND MARVELL SEMICONDUCTOR, INC.
AMENDMENT NUMBER 2
This AMENDMENT NUMBER 2 (this "Amendment Number 2") amends that certain
Master Development, Purchasing and License Agreement dated July 17, 2001 (the
"Effective Date"), as amended, by and between Intel Corporation ("Intel") and
Marvell Semiconductor Inc. ("Marvell")(the "Agreement") and is dated and is
effective as of July 17, 2001 (the "Second Amendment Effective Date"). Intel and
Marvell are each are "party" hereunder and, collectively, are the "parties"
hereunder.
RECITALS
WHEREAS, the parties entered into the Agreement on the Effective Date;
WHEREAS, the parties first amended the Agreement on October 18, 2000
(the "Amendment Effective Date");
WHEREAS, the parties seek to enter into this Amendment Number 2 because
the parties intend to *** which is not explicitly provided for in the Agreement,
as amended to date;
WHEREAS, the parties further seek to enter into this Amendment Number 2
because the parties intend to *** not explicitly provided for in the Agreement,
as amended to date;
WHEREAS, the parties wish to enter into this Amendment Number 2 to add a
new Exhibit C to the Agreement, as set forth in this Amendment Number 2;
WHEREAS, the parties wish to restate, adopt, republish and otherwise
agree to each and every other term of the Agreement, as amended to date, and
each exhibit thereto with the additional amendments set forth herein;
NOW, THEREFORE, in consideration of the foregoing premises and mutual covenants
set forth herein and in the Agreement, as amended to date, and for other good
and valuable consideration, the receipt and sufficiency of which the parties
hereby acknowledge, the parties hereby agree as follows:
1. Unless expressly set forth herein, each and every term and condition set
forth in the Agreement, as amended to date, and each Exhibit thereto shall
remain in full force and effect.
-------------
*** The confidential portions of this agreement omitted pursuant to a
confidential treatment request filed separately with the Securities and
Exchange Commission and are indicated by the symbol "***".
1
2
2. Unless expressly set for herein, all capitalized or defined terms herein
shall have meaning given such terms in the Agreement, as amended to date.
3. The parties hereby agree that the Agreement, as amended to date, shall be
further amended as follows:
3.1 Each term, condition and other item of information set forth in
Section 1.1 of the Agreement shall be deleted and replaced in their entirety
with the following:
"***"or "***" means *** developed by Marvell, designed to operate at a
designated *** and all fixes and revisions to such chip or updates with
substantially similar architecture thereto that is *** resulting in an
*** device.
3.2 Each term, condition and other item of information set in Section
1.2 of the Agreement shall be deleted and replaced in their entirety with the
following:
"Change of Control" of a party shall be deemed to have occurred if:
i) That party merges with or into a third party whether or not the
party is the surviving entity following such merger and as a result
of such merger holders of the party's securities prior to the
merger beneficially hold less than 51% of the capital stock of the
surviving entity of such merger;
ii) That party becomes a Subsidiary of a third party;
iii) A third party acquires all or substantially all of that party's
assets.
For the purposes of this definition of Change of Control in connection
with Marvell, "party" means Marvell Technology Group, Ltd., a Bermuda
corporation, or Marvell Semiconductor, Inc., or both. For additional
purposes hereof, a Change of Control in connection with Marvell shall
not be deemed to have occurred with respect to a party in the event that
party becomes a Subsidiary of or controlled by or comes under the
control of any entity that is controlled by or under the control of
Marvell."
3.3 Each term, condition and other item of information set forth in
Section 1.3 of the Agreement shall be deleted and replaced in their entirety
with the following:
"FCS" or First Customer Shipment means the date on which Intel first
makes generally available for purchase an *** device. The exact *** is
called "***, which means the point in the development process at which
an *** device can be *** with no waiver and in high volume.
3.4 The parties agree that the following additional Section 1.20 shall
be inserted into the Agreement after Section 1.19:
***
3.5 Each term, condition and other item of information set forth in
Section 1.4 of the Agreement shall be deleted and replaced in their entirety
with the following:
"*** means single chip development projects in which an *** and a ***
pursuant to the terms of the Agreement, as amended to date, and ***,
including, but not limited to, individually and collectively, "*** be
developed *** be developed at ***."
-------------
*** The confidential portions of this agreement omitted pursuant to a
confidential treatment request filed separately with the Securities and
Exchange Commission and are indicated by the symbol "***".
2
3
3.6 Each term, condition and other item of information set forth in
Section 1.11 of the Agreement shall be deleted and replaced in their entirety
with the following:
"***" means the code name for the project that will manage and produce
the initial *** device developed by the parties pursuant to the
Agreement, as amended to date, which the parties originally designated
as "***".
3.7 The parties agree that the following additional Section 1.22 shall
be inserted into the Agreement after Section 1.21:
"***" shall mean the following companies and their Subsidiaries***."
3.8 The parties agree that the following additional Section 1.23 shall
be inserted into the Agreement after Section 1.22:
"***" shall mean the following companies and their Subsidiaries: ***."
3.9 The parties agree that the following additional section 1.24 shall
be inserted into the Agreement after Section 1.23:
"***" means the commitment from a *** and *** to design, develop and
ship a model or line(s) of personal computers, which incorporate(s) an
*** solution."
3.10 The parties agree that the following additional Section 13 shall be
inserted into the Agreement after Section 12:
"13. ***
This Agreement, as amended to date, contains the entire terms and
conditions that shall apply to projects undertaken by the parties that
are the subject of the Agreement, as amended to date and the subject of
the ***, as attached hereto as Exhibit C. The parties agree that ***
will identify *** to be undertaken by the parties. The parties further
agree that *** typically will be related *** efforts, but may also
include as their subject matter ***.
13.1 Procedure for Entering into ***. Each *** issued under this
Agreement shall become an effective and binding obligation of each party
only when duly authorized representatives of each party shall have
properly executed such ***. Each *** executed entered under this
Agreement, as amended to date, shall incorporate the provisions of, be
governed by and made a part of the Agreement. In the event any term or
condition of a *** conflicts with any term or condition of this
Agreement, the terms and conditions of the Agreement shall govern.
13.2 Contents of Each ***. Each *** shall contain (or incorporate as
attachments or by reference) any or all of the following items, if
necessary:
(1) A reference to this Agreement and the incorporation of the
Project Statement thereto;
(2) Designation of the names, business addresses, and telephone
numbers of the parties' individual employee's who shall manage
the development or other efforts under the ***;
(3) Incorporation or reference to applicable product specifications,
if any;
-------------
*** The confidential portions of this agreement omitted pursuant to a
confidential treatment request filed separately with the Securities and
Exchange Commission and are indicated by the symbol "***".
3
4
(4) A description of the product(s), generally including product
codes and the product contents, if any;
(5) *** of *** required to achieve ***;
(6) Amount, schedule and method of compensation ***, if any;
(7) Statement of Work and timetable for the performance and
completion, including milestones, the party responsible for each
milestone and delivery dates, where appropriate;
(8) The terms and conditions of any license required under any such
*** and,
(9) Any other term or condition the parties deem advisable to
include in such ***, including but not limited to quality and
support.
***."
13.3 ***."
3.11 Each term, condition and other item of information set forth in
Section 6 of Exhibit B of the Agreement, but excluding Sections 6.A. through 6.
G., shall be deleted and replaced in their entirety with the following:
"6. DELIVERY, RELEASES SCHEDULING AND ALLOCATION.
The management of existing accepted Releases for the *** will, to the
extent commercially reasonable, occur in accordance with the following
Table 1. The parties agree that any charges incurred from any upside
order Intel places pursuant to the following Table 1 in this Section 6
for upside orders of the *** will be invoiced and paid in accordance
with this Exhibit B.
TABLE 1
----------------- ---------
Days prior to Upside
delivery
----------------- ---------
*** ***
----------------- ---------
*** ***
----------------- ---------
*** ***
----------------- ---------
The management of existing accepted Releases for an *** device will, to
the extent commercially reasonable, occur in accordance with the
following Table 2. The parties agree *** of any and all expediting
charges *** incurs in connection with *** pursuant to the following
Table 2 in this Section 6 for upside orders of any *** device;
otherwise, the parties agree that any charges incurred in this Section 6
will be invoiced and paid in accordance with this Exhibit B.
TABLE 2
----------------- ---------
Days prior to Upside
delivery
----------------- ---------
*** ***
----------------- ---------
*** ***
----------------- ---------
*** ***
----------------- ---------
*** ***
----------------- ---------
*** ***
----------------- ---------
-------------
*** The confidential portions of this agreement omitted pursuant to a
confidential treatment request filed separately with the Securities and
Exchange Commission and are indicated by the symbol "***".
4
5
3.12 Each term, condition and other item of information set forth in
Section 6.G. of Exhibit B of the Agreement shall be deleted and replaced in
their entirety with the following:
"Notwithstanding anything else in this Agreement, failure to meet the
delivery date(s) that comply with the terms of this Agreement in the
Purchase Order for the *** *** or *** other than for force majeure,
within *** days after such scheduled delivery date(s), shall be
considered a material breach of contract and shall *** without any
liability."
3.13 The parties agree that the *** attached to this Amendment Number 2,
and identified herein as ***, respectively, shall be attached to the Agreement,
as amended to date, as Exhibit C, collectively.
3.14 The parties agree that the following additional Section 14 shall be
inserted into the Agreement after additional Section 13:
"14. CALENDAR YEAR ***
Notwithstanding the provisions of Section 11.3 and ***, as amended to
date, in any calendar year in which the parties enter into a Project
Statement for the development of an *** device to be developed in such
year or a succeeding calendar year, *** for any single chip device ***.
It is the parties intent that *** for such device related to such ***."
3.15 Each term, condition and other item of information set forth in
Section 4.2(c) of the Agreement, as amended, shall be deleted and replaced in
their entirety with the following:
"*** ***.
3.16 The parties agree that the following additional Section 15 shall be
inserted into the Agreement after additional Section 14:
"15. ADDITIONAL OBLIGATIONS OF THE PARTIES
15.1 Provided that *** its obligations set forth in Section 15.2 below,
*** any development activities with *** any device *** device developed
hereunder ***.
15.2 *** commercially reasonable efforts to cooperate *** device *** and
to *** for all such ***, *** of the *** for such ***. *** commercially
reasonable efforts, at a minimum, may include, but are not limited to:
1) ***, including, but not limited to, holding *** and conducting ***.
The parties agree that the restrictions set forth in Section 15.1 ***
with respect *** in the event *** *** by failing to provide Marvell with
*** *** *** opportunity.
15.3 *** ***.
15.4 ***.
3.17 Each term, condition and other item of information set forth in
Section 11.1 of the Agreement, as amended, shall be deleted and replaced in
their entirety with the following:
"Term. Except for *** set forth in ***, which such obligations shall
expire in accordance with the terms ***, unless ***, the term of this
Agreement will expire with respect to each ***
-------------
*** The confidential portions of this agreement omitted pursuant to a
confidential treatment request filed separately with the Securities and
Exchange Commission and are indicated by the symbol "***".
5
6
*** entered into by and between the parties *** developed under such***.
***."
4. The parties agree to commence development work on another *** part (the ***
product (or the replacement therefor)) on or before the expiration of *** with
an ***, if the parties agree that another part is needed in the aforementioned
timeframe.
5. The Agreement as amended to date, and this Amendment Number 2, along with
Attachment Number 1 hereto, are to be read together as one document. If any term
or condition of this Amendment Number 2 shall conflict with any term or
condition of the Agreement, as amended to date, then the Agreement, as amended
to date, shall govern such conflicting provision.
6. The parties agree to *** that will advance the sales of all products under
the Agreement, as amended to date, and each ***.
-------------
*** The confidential portions of this agreement omitted pursuant to a
confidential treatment request filed separately with the Securities and
Exchange Commission and are indicated by the symbol "***".
6
7
7. This Amendment Number 2 and Attachment Number 1 hereon, and the Agreement, as
amended to date, constitute the entire agreement between the parties relating to
the subject matter herein, thereon and therein and supersedes all prior and
contemporaneous agreements, discussions, negotiations, and understandings
between the parties.
IN WITNESS WHEREOF, the parties, by and through their respective
representatives, hereby execute this Amendment Number 2.
INTEL CORPORATION MARVELL SEMICONDUCTOR, INC.
By: ____________________________ By: ________________________________
Name: __________________________ Name: ______________________________
Title: _________________________ Title: _____________________________
7
8
Intel-Marvell Confidential
ATTACHMENT NUMBER 1:
EXHIBIT C:
***
1
-------------
*** The confidential portions of this agreement omitted pursuant to a
confidential treatment request filed separately with the Securities and
Exchange Commission and are indicated by the symbol "***".
9
Intel-Marvell Confidential
VER: V1.0
***
--------------------------------------------------------------------------------
1.0 INCORPORATION INTO AGREEMENT
The parties agree that this *** shall be attached to and incorporated into the
Agreement as *** to Exhibit C thereof. The purpose of this *** is to set forth
the terms and conditions under which Marvell shall ***
Any changes to the specifications of the *** that are set forth in this *** must
be agreed to by the parties in writing.
2.0 DEFINITIONS
The *** is a repackaged version of the *** product.
3.0 PRODUCT DESCRIPTIONS
***
4.0 PRICING
4.1 ***
---------- -------- -------- -------- ------- -------- -------- --------
*** *** *** *** *** *** *** ***
---------- -------- -------- -------- ------- -------- -------- --------
*** *** *** *** *** *** *** ***
---------- -------- -------- -------- ------- -------- -------- --------
4.1.2 ***
5.0 STATEMENT OF WORK -- PROJECT DELIVERABLES AND SCHEDULE
5.1 PURPOSE
***
5.2 PROJECT MANAGEMENT
The parties agree to each assign dedicated Project Managers and
Engineering Managers to this project. The Intel Project Manager will have
overall project responsibility.
***
------------- ----------------- ---------------- ---------------- ------------------------
*** *** *** *** ***
------------- ----------------- ---------------- ---------------- ------------------------
*** *** *** *** ***
------------- ----------------- ---------------- ---------------- ------------------------
*** *** *** *** ***
------------- ----------------- ---------------- ---------------- ------------------------
*** *** *** *** ***
------------- ----------------- ---------------- ---------------- ------------------------
*** *** *** *** ***
------------- ----------------- ---------------- ---------------- ------------------------
In addition, when applicable, both parties agree to assign cross-functional team
members to the project. These members will include employees of each party
representing, but not limited to, the following functions or disciplines:
-------------
*** The confidential portions of this agreement omitted pursuant to a
confidential treatment request filed separately with the Securities and
Exchange Commission and are indicated by the symbol "***".
2
10
Intel-Marvell Confidential
***
5.3 PRODUCT REQUIREMENTS AND SPECIFICATIONS
The following describes the *** product requirements and is incorporated
herein.
***
-------------
*** "The confidential portions of this agreement omitted pursuant to a
confidential treatment request filed separately with the Securities and
Exchange Commission and are indicated by the symbol "***"."
3
11
Intel-Marvell Confidential
5.4 SOW, PROJECT DELIVERABLES, SCHEDULE, RESTRICTION ON USE AND
NON-DISCLOSURE OF PARTIES' INTELLECTUAL PROPERTY
***
6.0 NRE AND QA CONFORMANCE COSTS PAYMENT SCHEDULES
***
***
------------------------------------------------- -------------
*** ***
------------------------------------------------- -------------
*** ***
------------------------------------------------- -------------
Notwithstanding the foregoing Schedule PS1-A, ***
Notwithstanding the foregoing Schedule PS1-A, ***
7.0 DESIGNATED PROJECT MANAGERS AND TECHNICAL POINTS OF CONTACT
For Marvell: For Intel:
***
-------------
*** The confidential portions of this agreement omitted pursuant to a
confidential treatment request filed separately with the Securities and
Exchange Commission and are indicated by the symbol "***".
4
12
Intel-Marvell Confidential
INTEL CORPORATION MARVELL SEMICONDUCTOR, INC.
By: _________________________________ By:_________________________________
Printed Name: _______________________ Printed Name: ______________________
Title: ______________________________ Title: _____________________________
Date: _______________________________ Date: ______________________________
5
13
Intel-Marvell Confidential
***
STATEMENT OF WORK ("SOW")
PHASE I: ******
-------------- ------ ------ ------------------------------------------------------ --------------- ---------
MS TARGET TARGET ACTIVITY/DELIVERABLE BY/ TO
START END BETWEEN
MONTH MONTH
& &
YEAR YEAR
-------------- ------ ------ ------------------------------------------------------ --------------- ---------
*** *** *** *** *** ***
-------------- ------ ------ ------------------------------------------------------ --------------- ---------
*** *** *** *** *** ***
-------------- ------ ------ ------------------------------------------------------ --------------- ---------
*** *** *** *** *** ***
-------------- ------ ------ ------------------------------------------------------ --------------- ---------
*** *** *** *** *** ***
-------------- ------ ------ ------------------------------------------------------ --------------- ---------
PHASE II: ***
-------------- ------ ------ ------------------------------------------------------ --------------- ---------
MS TARGET TARGET ACTIVITY/DELIVERABLE BY/ TO
START END BETWEEN
MONTH MONTH
& &
YEAR YEAR
-------------- ------ ------ ------------------------------------------------------ --------------- ---------
*** *** *** *** *** ***
-------------- ------ ------ ------------------------------------------------------ --------------- ---------
*** *** *** *** *** ***
-------------- ------ ------ ------------------------------------------------------ --------------- ---------
PHASE III: SILICON / SYSTEM VERIFICATION
-------------- ------ ------ ------------------------------------------------------ --------------- ---------
MS TARGET TARGET ACTIVITY/DELIVERABLE BY/ TO
START END BETWEEN
MONTH MONTH
& &
YEAR YEAR
-------------- ------ ------ ------------------------------------------------------ --------------- ---------
*** *** *** *** *** ***
---------------- -- ------------- ------------------------------------------------------- ----------- ---------
-------------
*** The confidential portions of this agreement omitted pursuant to a
confidential treatment request filed separately with the Securities and
Exchange Commission and are indicated by the symbol "***".
6
14
Intel-Marvell Confidential
-------------- ------ ------ ------------------------------------------------------ --------------- ---------
*** *** *** *** *** ***
-------------- ------ ------ ------------------------------------------------------ --------------- ---------
*** *** *** *** *** ***
-------------- ------ ------ ------------------------------------------------------ --------------- ---------
*** *** *** *** *** ***
-------------- ------ ------ ------------------------------------------------------ --------------- ---------
*** *** *** *** *** ***
-------------- ------ ------ ------------------------------------------------------ --------------- ---------
*** *** *** *** *** ***
-------------- ------ ------ ------------------------------------------------------ --------------- ---------
*** *** *** *** *** ***
-------------- ------ ------ ------------------------------------------------------ --------------- ---------
INTEL CORPORATION MARVELL SEMICONDUCTOR, INC.
By: _________________________________ By:_________________________________
Printed Name: _______________________ Printed Name: ______________________
Title: ______________________________ Title: _____________________________
Date: _______________________________ Date: ______________________________
-------------
*** "The confidential portions of this agreement omitted pursuant to a
confidential treatment request filed separately with the Securities and
Exchange Commission and are indicated by the symbol "***"."
7
15
Intel-Marvell Confidential
***
ACCEPTANCE CRITERIA
***
PHASE I
------------------- -----------------------------------------------------------------------
SOW MS ACCEPTANCE CRITERIA
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
PHASE II
------------------- -----------------------------------------------------------------------
SOW MS ACCEPTANCE CRITERIA
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
PHASE III
------------------- -----------------------------------------------------------------------
SOW MS ACCEPTANCE CRITERIA
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
-------------
*** The confidential portions of this agreement omitted pursuant to a
confidential treatment request filed separately with the Securities and
Exchange Commission and are indicated by the symbol "***".
8
16
Intel-Marvell Confidential
INTEL CORPORATION MARVELL SEMICONDUCTOR, INC.
By: ________________________________ By:__________________________________
Printed Name: ______________________ Printed Name: _______________________
Title: _____________________________ Title: ______________________________
Date: ______________________________ Date: _______________________________
9
17
INTEL-MARVELL CONFIDENTIAL
VER: V1.0
***
--------------------------------------------------------------------------------
1.0 INCORPORATION INTO AGREEMENT
The parties agree that this *** shall be attached to and incorporated into the
Agreement as *** to Exhibit C thereof. The purpose of this *** is to set forth
the terms and conditions ***.
Any changes to the specifications of the *** that are set forth in this *** must
be agreed to by the parties in writing.
2.0 DEFINITIONS AND PRODUCT DESCRIPTION
***.
3.0 GUIDELINE PRICING
3.1 ***3.1.1 ***
---------- -------- --------
*** *** ***
---------- -------- --------
*** *** ***
---------- -------- --------
3.1.2 ***.
4.0 STATEMENT OF WORK -- PROJECT DELIVERABLES AND SCHEDULE
4.1 PURPOSE
***.
4.2 DEFINITIONS
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
-------------
*** The confidential portions of this agreement omitted pursuant to a
confidential treatment request filed separately with the Securities and
Exchange Commission and are indicated by the symbol "***".
1
18
INTEL-MARVELL CONFIDENTIAL
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
-------------
*** "The confidential portions of this agreement omitted pursuant to a
confidential treatment request filed separately with the Securities and
Exchange Commission and are indicated by the symbol "***"."
2
19
INTEL-MARVELL CONFIDENTIAL
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
5.0 PROJECT MANAGEMENT
The parties agree to each assign dedicated Project Managers and Engineering
Managers to this project. The Intel Project Manager will have overall project
responsibility.
***
------------- ----------------- ---------------- ---------------- ------------------------
*** *** *** *** ***
------------- ----------------- ---------------- ---------------- ------------------------
*** *** *** *** ***
------------- ----------------- ---------------- ---------------- ------------------------
*** *** *** *** ***
------------- ----------------- ---------------- ---------------- ------------------------
*** *** *** *** ***
------------- ----------------- ---------------- ---------------- ------------------------
*** *** *** *** ***
------------- ----------------- ---------------- ---------------- ------------------------
In addition, when applicable, both parties agree to assign cross-functional team
members to the *** development project. These members will include employees of
each party representing, but not limited to, the following functions or
disciplines:
***
6.0 PRODUCT REQUIREMENTS AND SPECIFICATIONS
The following documents describe the *** product requirements and are
incorporated herein.
***.
7.0 STATEMENT OF WORK ("SOW") -- PROJECT DELIVERABLES AND SCHEDULE;
RESTRICTION ON USE AND DISCLOSURE OF PARTIES' INTELLECTUAL PROPERTY
***.
8.0 NRE AND QA CONFORMANCE COSTS PAYMENT SCHEDULES
***:
-------------
*** The confidential portions of this agreement omitted pursuant to a
confidential treatment request filed separately with the Securities and
Exchange Commission and are indicated by the symbol "***".
3
20
INTEL-MARVELL CONFIDENTIAL
SCHEDULE PS2-A
------------------------------------------------ -------------- --------------
Milestone Material Resource
Payment Payment
------------------------------------------------ -------------- --------------
*** *** ***
------------------------------------------------ -------------- --------------
*** *** ***
------------------------------------------------ -------------- --------------
*** *** ***
------------------------------------------------ -------------- --------------
***
***
9.0 ***
9.1 ***
***
***:
***
------------------------------- -------
*** ***
------------------------------- -------
*** ***
------------------------------- -------
*** ***
------------------------------- -------
*** ***
------------------------------- -------
*** ***
------------------------------- -------
***
***
***
***
10.0 DESIGNATED PROJECT MANAGERS AND TECHNICAL POINTS OF CONTACT
***
***
INTEL CORPORATION MARVELL SEMICONDUCTOR, INC.
By: ________________________________ By:__________________________________
Printed Name: ______________________ Printed Name: _______________________
Title: _____________________________ Title: ______________________________
Date: ______________________________ Date: _______________________________
-------------
*** "The confidential portions of this agreement omitted pursuant to a
confidential treatment request filed separately with the Securities and
Exchange Commission and are indicated by the symbol "***"."
4
21
INTEL-MARVELL CONFIDENTIAL
5
22
INTEL-MARVELL CONFIDENTIAL
***
REQUIRED FEATURES OF ***
*** PRODUCT REQUIREMENTS
REQUIRED FEATURES
***
-------------
*** The confidential portions of this agreement omitted pursuant to a
confidential treatment request filed separately with the Securities and
Exchange Commission and are indicated by the symbol "***".
6
23
INTEL-MARVELL CONFIDENTIAL
INTEL CORPORATION MARVELL SEMICONDUCTOR, INC.
By: ________________________________ By:__________________________________
Printed Name: ______________________ Printed Name: _______________________
Title: _____________________________ Title: ______________________________
Date: ______________________________ Date: _______________________________
7
24
INTEL-MARVELL CONFIDENTIAL
***
***
PART I: ***
The purpose of this section is to provide a framework for the ***. The *** will
be completed to specifications *** changes to *** mutually agreed upon by both
parties. The actual IAS document will be written, managed, ***.
PART II: DETAILS OF ***
***
***
***
INTEL CORPORATION MARVELL SEMICONDUCTOR, INC.
By: _________________________________ By:_________________________________
Printed Name: _______________________ Printed Name: ______________________
Title: ______________________________ Title: _____________________________
Date: _______________________________ Date: ______________________________
-------------
*** The confidential portions of this agreement omitted pursuant to a
confidential treatment request filed separately with the Securities and
Exchange Commission and are indicated by the symbol "***".
8
25
***
STATEMENT OF WORK ("SOW")
PHASE I: ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
MS TARGET TARGET ACTIVITY/DELIVERABLE BY/ TO
START END BETWEEN
MONTH MONTH
& YEAR & YEAR
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
PHASE II: ***
---------- -------- -------- ----------------------------------------------------- -------- --------
MS TARGET TARGET ACTIVITY/DELIVERABLE BY/ TO
START END BETWEEN
MONTH MONTH
& YEAR & YEAR
---------- -------- -------- ----------------------------------------------------- -------- --------
*** *** *** *** *** ***
---------- -------- -------- ----------------------------------------------------- -------- --------
*** *** ***
*** *** ***
---------- -------- -------- ----------------------------------------------------- -------- --------
*** *** ***
*** *** ***
---------- -------- -------- ----------------------------------------------------- -------- --------
*** *** ***
*** *** ***
---------- -------- -------- ----------------------------------------------------- -------- --------
*** *** ***
*** *** ***
---------- -------- -------- ----------------------------------------------------- -------- --------
*** *** ***
*** *** ***
---------- -------- -------- ----------------------------------------------------- -------- --------
-------------
*** The confidential portions of this agreement omitted pursuant to a
confidential treatment request filed separately with the Securities and
Exchange Commission and are indicated by the symbol "***".
9
26
INTEL-MARVELL CONFIDENTIAL
---------- -------- -------- ----------------------------------------------------- -------- --------
*** *** *** *** *** ***
---------- -------- -------- ----------------------------------------------------- -------- --------
*** *** *** *** *** ***
---------- -------- -------- ----------------------------------------------------- -------- --------
*** *** *** *** *** ***
---------- -------- -------- ----------------------------------------------------- -------- --------
*** *** *** *** *** ***
---------- -------- -------- ----------------------------------------------------- -------- --------
*** *** *** *** *** ***
---------- -------- -------- ----------------------------------------------------- -------- --------
*** *** *** *** *** ***
---------- -------- -------- ----------------------------------------------------- -------- --------
*** *** *** *** *** ***
---------- -------- -------- ----------------------------------------------------- -------- --------
*** *** *** *** *** ***
---------- -------- -------- ----------------------------------------------------- -------- --------
*** *** *** *** *** ***
---------- -------- -------- ----------------------------------------------------- -------- --------
*** *** *** *** *** ***
---------- -------- -------- ----------------------------------------------------- -------- --------
*** *** *** *** *** ***
---------- -------- -------- ----------------------------------------------------- -------- --------
*** *** *** *** *** ***
---------- -------- -------- ----------------------------------------------------- -------- --------
*** *** *** *** *** ***
---------- -------- -------- ----------------------------------------------------- -------- --------
*** *** *** *** *** ***
---------- -------- -------- ----------------------------------------------------- -------- --------
*** *** *** *** *** ***
---------- -------- -------- ----------------------------------------------------- -------- --------
*** *** *** *** *** ***
---------- -------- -------- ----------------------------------------------------- -------- --------
*** *** *** *** *** ***
---------- -------- -------- ----------------------------------------------------- -------- --------
*** *** *** *** *** ***
---------- -------- -------- ----------------------------------------------------- -------- --------
*** *** *** *** *** ***
---------- -------- -------- ----------------------------------------------------- -------- --------
-------------
*** "The confidential portions of this agreement omitted pursuant to a
confidential treatment request filed separately with the Securities and
Exchange Commission and are indicated by the symbol "***"."
▇▇
▇▇
▇▇▇▇▇-▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇▇
▇▇▇▇▇ ▇▇▇: ***
--------- --------- -------- ------------------------------------------------------- ------------ ---------
MS TARGET TARGET ACTIVITY/DELIVERABLE BY/ BETWEEN TO
START END
MONTH MONTH
& YEAR & YEAR
--------- --------- -------- ------------------------------------------------------- ------------ ---------
*** *** *** *** *** ***
--------- --------- -------- ------------------------------------------------------- ------------ ---------
*** *** *** *** *** ***
--------- --------- -------- ------------------------------------------------------- ------------ ---------
*** *** *** *** *** ***
--------- --------- -------- ------------------------------------------------------- ------------ ---------
*** *** *** *** *** ***
--------- --------- -------- ------------------------------------------------------- ------------ ---------
*** *** *** *** *** ***
--------- --------- -------- ------------------------------------------------------- ------------ ---------
*** *** *** *** *** ***
--------- --------- -------- ------------------------------------------------------- ------------ ---------
*** *** *** *** *** ***
--------- --------- -------- ------------------------------------------------------- ------------ ---------
*** *** *** *** *** ***
--------- --------- -------- ------------------------------------------------------- ------------ ---------
*** *** *** *** *** ***
--------- --------- -------- ------------------------------------------------------- ------------ ---------
*** *** *** *** *** ***
--------- --------- -------- ------------------------------------------------------- ------------ ---------
*** *** *** *** *** ***
--------- --------- -------- ------------------------------------------------------- ------------ ---------
-------------
*** "The confidential portions of this agreement omitted pursuant to a
confidential treatment request filed separately with the Securities and
Exchange Commission and are indicated by the symbol "***"."
11
28
INTEL-MARVELL CONFIDENTIAL
INTEL CORPORATION MARVELL SEMICONDUCTOR, INC.
By: _________________________________ By:_________________________________
Printed Name: _______________________ Printed Name: ______________________
Title: ______________________________ Title: _____________________________
Date: _______________________________ Date: ______________________________
12
29
INTEL-MARVELL CONFIDENTIAL
***
ACCEPTANCE CRITERIA
***
PHASE I
------------------- -----------------------------------------------------------------------
SOW MS ACCEPTANCE CRITERIA
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
PHASE II
------------------- -----------------------------------------------------------------------
SOW MS ACCEPTANCE CRITERIA
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
PHASE III
------------------- -----------------------------------------------------------------------
CORRESPONDING ACCEPTANCE CRITERIA
------------------- -----------------------------------------------------------------------
-------------
*** The confidential portions of this agreement omitted pursuant to a
confidential treatment request filed separately with the Securities and
Exchange Commission and are indicated by the symbol "***".
13
30
INTEL-MARVELL CONFIDENTIAL
------------------- -----------------------------------------------------------------------
SOW MS
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
INTEL CORPORATION MARVELL SEMICONDUCTOR, INC.
By: ________________________________ By:__________________________________
Printed Name: ______________________ Printed Name: _______________________
Title: _____________________________ Title: ______________________________
Date: ______________________________ Date: _______________________________
-------------
*** "The confidential portions of this agreement omitted pursuant to a
confidential treatment request filed separately with the Securities and
Exchange Commission and are indicated by the symbol "***"."
14
31
INTEL-MARVELL CONFIDENTIAL
***
***
-------------- ----- -------- ------- -------------------- ---------------- ------------------- -------
STRESS RISK # LOTS UNITS/ PTQ GOAL PDQ RQMT FLQ RQMT NOTES
TOTAL LOT
-------------- ----- -------- ------- -------------------- ---------------- ------------------- -------
*** *** *** *** *** *** *** ***
-------------- ----- -------- ------- -------------------- ---------------- ------------------- -------
*** *** *** *** *** *** *** ***
-------------- ----- -------- ------- -------------------- ---------------- ------------------- -------
*** *** *** *** *** *** *** ***
-------------- ----- -------- ------- -------------------- ---------------- ------------------- -------
*** *** *** *** *** *** *** ***
-------------- ----- -------- ------- -------------------- ---------------- ------------------- -------
*** *** *** *** *** *** *** ***
-------------- ----- -------- ------- -------------------- ---------------- ------------------- -------
*** *** *** *** *** *** *** ***
-------------- ----- -------- ------- -------------------- ---------------- ------------------- -------
*** *** *** *** *** *** *** ***
-------------- ----- -------- ------- -------------------- ---------------- ------------------- -------
*** *** *** *** *** *** *** ***
-------------- ----- -------- ------- -------------------- ---------------- ------------------- -------
*** *** *** *** *** *** *** ***
-------------- ----- -------- ------- -------------------- ---------------- ------------------- -------
*** *** *** *** *** *** *** ***
-------------- ----- -------- ------- -------------------- ---------------- ------------------- -------
*** *** *** *** *** *** *** ***
-------------- ----- -------- ------- -------------------- ---------------- ------------------- -------
NOTES:
***
INTEL CORPORATION MARVELL SEMICONDUCTOR, INC.
By: ________________________________ By:__________________________________
Printed Name: ______________________ Printed Name: _______________________
Title: _____________________________ Title: ______________________________
Date: ______________________________ Date: _______________________________
-------------
*** The confidential portions of this agreement omitted pursuant to a
confidential treatment request filed separately with the Securities and
Exchange Commission and are indicated by the symbol "***".
15
32
INTEL-MARVELL CONFIDENTIAL
VER: V1.0
***
--------------------------------------------------------------------------------
1.0 INCORPORATION INTO AGREEMENT
The parties agree that this *** shall be attached to and incorporated into the
Agreement as *** to Exhibit C thereof. The purpose of this *** is to set forth
the terms and conditions under which ***.
Any changes to the specifications of *** Product that are set forth in this
*** must be agreed to by the parties in writing.
2.0 DEFINITIONS AND PRODUCT DESCRIPTION
***
3.0 PRICING
***
---------- -------- ---------- --------- ---------- ---------- --------- -----------
*** *** *** *** *** *** *** ***
---------- -------- ---------- --------- ---------- ---------- --------- -----------
*** *** *** *** *** *** *** ***
---------- -------- ---------- --------- ---------- ---------- --------- -----------
***
4.0 STATEMENT OF WORK -- PROJECT DELIVERABLES AND SCHEDULE
4.1 PURPOSE
***
4.2 DEFINITIONS
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
-------------
*** The confidential portions of this agreement omitted pursuant to a
confidential treatment request filed separately with the Securities and
Exchange Commission and are indicated by the symbol "***".
1
33
INTEL-MARVELL CONFIDENTIAL
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
-------------
*** "The confidential portions of this agreement omitted pursuant to a
confidential treatment request filed separately with the Securities and
Exchange Commission and are indicated by the symbol "***"."
2
34
INTEL-MARVELL CONFIDENTIAL
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
5.0 PROJECT MANAGEMENT
The parties agree to each assign dedicated Project Managers and Engineering
Managers to this project. The Intel Project Manager will have overall project
responsibility.
***
------------- ----------------- ---------------- ---------------- ------------------------
*** *** *** *** ***
------------- ----------------- ---------------- ---------------- ------------------------
*** *** *** *** ***
------------- ----------------- ---------------- ---------------- ------------------------
*** *** *** *** ***
------------- ----------------- ---------------- ---------------- ------------------------
*** *** *** *** ***
------------- ----------------- ---------------- ---------------- ------------------------
*** *** *** *** ***
------------- ----------------- ---------------- ---------------- ------------------------
In addition, when applicable, both parties agree to assign cross-functional team
members to the *** development project. These members will include employees of
each party representing, but not limited to, the following functions or
disciplines:
***
6.0 PRODUCT REQUIREMENTS AND SPECIFICATIONS
***.
7.0 STATEMENT OF WORK ("SOW") -- PROJECT DELIVERABLES AND SCHEDULE;
RESTRICTION ON USE AND DISCLOSURE OF PARTIES' INTELLECTUAL PROPERTY
***
8.0 NRE AND QA CONFORMANCE COSTS PAYMENT SCHEDULES
***
------------------------------------------------ -----------------
*** ***
------------------------------------------------ -----------------
-------------
*** The confidential portions of this agreement omitted pursuant to a
confidential treatment request filed separately with the Securities and
Exchange Commission and are indicated by the symbol "***".
3
35
INTEL-MARVELL CONFIDENTIAL
------------------------------------------------ -----------------
*** ***
------------------------------------------------ -----------------
Notwithstanding the foregoing ***
Notwithstanding the foregoing ***
-------------
*** The confidential portions of this agreement omitted pursuant to a
confidential treatment request filed separately with the Securities and
Exchange Commission and are indicated by the symbol "***".
4
36
INTEL-MARVELL CONFIDENTIAL
10.0 DESIGNATED PROJECT MANAGERS AND TECHNICAL POINTS OF CONTACT
For Marvell: For Intel:
***
INTEL CORPORATION MARVELL SEMICONDUCTOR, INC.
By: ________________________________ By:__________________________________
Printed Name: ______________________ Printed Name: _______________________
Title: _____________________________ Title: ______________________________
Date: ______________________________ Date: _______________________________
-------------
*** "The confidential portions of this agreement omitted pursuant to a
confidential treatment request filed separately with the Securities and
Exchange Commission and are indicated by the symbol "***"."
5
37
INTEL-MARVELL CONFIDENTIAL
***
REQUIRED FEATURES OF ***
*** PRODUCT REQUIREMENTS
REQUIRED FEATURES
*** FEATURES:
***
INTEL CORPORATION MARVELL SEMICONDUCTOR, INC.
By: ________________________________ By:__________________________________
Printed Name: ______________________ Printed Name: _______________________
Title: _____________________________ Title: ______________________________
Date: ______________________________ Date: _______________________________
-------------
*** The confidential portions of this agreement omitted pursuant to a
confidential treatment request filed separately with the Securities and
Exchange Commission and are indicated by the symbol "***".
6
38
INTEL-MARVELL CONFIDENTIAL
***
***
PART I: ***
***
***
INTEL CORPORATION MARVELL SEMICONDUCTOR, INC.
By: ________________________________ By:__________________________________
Printed Name: ______________________ Printed Name: _______________________
Title: _____________________________ Title: ______________________________
Date: ______________________________ Date: _______________________________
-------------
*** The confidential portions of this agreement omitted pursuant to a
confidential treatment request filed separately with the Securities and
Exchange Commission and are indicated by the symbol "***".
7
39
INTEL-MARVELL CONFIDENTIAL
***
STATEMENT OF WORK ("SOW")
PHASE I: ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
MS TARGET TARGET ACTIVITY/DELIVERABLE BY/ TO
START END BETWEEN
MONTH MONTH
& YEAR & YEAR
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
PHASE II: ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
MS TARGET TARGET ACTIVITY/DELIVERABLE BY/ TO
START END BETWEEN
MONTH MONTH
& YEAR & YEAR
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
-------------
*** The confidential portions of this agreement omitted pursuant to a
confidential treatment request filed separately with the Securities and
Exchange Commission and are indicated by the symbol "***".
8
40
INTEL-MARVELL CONFIDENTIAL
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
---------- --------- ---------- ------------------------------------------------------ ------------- --------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
-------------
*** "The confidential portions of this agreement omitted pursuant to a
confidential treatment request filed separately with the Securities and
Exchange Commission and are indicated by the symbol "***"."
9
41
INTEL-MARVELL CONFIDENTIAL
PHASE III: ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
MS TARGET TARGET ACTIVITY/DELIVERABLE BY/ TO
START END BETWEEN
MONTH MONTH
& YEAR & YEAR
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
-------------
*** "The confidential portions of this agreement omitted pursuant to a
confidential treatment request filed separately with the Securities and
Exchange Commission and are indicated by the symbol "***"."
10
42
INTEL-MARVELL CONFIDENTIAL
INTEL CORPORATION MARVELL SEMICONDUCTOR, INC.
By: ________________________________ By:__________________________________
Printed Name: ______________________ Printed Name: _______________________
Title: _____________________________ Title: ______________________________
Date: ______________________________ Date: _______________________________
11
43
INTEL-MARVELL CONFIDENTIAL
***
ACCEPTANCE CRITERIA
***:
PHASE I
------------------- -----------------------------------------------------------------------
SOW MS ACCEPTANCE CRITERIA
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
PHASE II
------------------- -----------------------------------------------------------------------
SOW MS ACCEPTANCE CRITERIA
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
PHASE III
---------------- -------------------------------------------------------------------------------
CORRESPONDING ACCEPTANCE CRITERIA
---------------- -------------------------------------------------------------------------------
-------------
*** The confidential portions of this agreement omitted pursuant to a
confidential treatment request filed separately with the Securities and
Exchange Commission and are indicated by the symbol "***".
12
44
INTEL-MARVELL CONFIDENTIAL
------------------- -----------------------------------------------------------------------
NG SOW MS
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
-------------
*** "The confidential portions of this agreement omitted pursuant to a
confidential treatment request filed separately with the Securities and
Exchange Commission and are indicated by the symbol "***"."
13
45
INTEL-MARVELL CONFIDENTIAL
INTEL CORPORATION MARVELL SEMICONDUCTOR, INC.
By: _______________________________ By:___________________________________
Printed Name: _____________________ Printed Name: ________________________
Title: ____________________________ Title: _______________________________
Date: _____________________________ Date: ________________________________
14
46
INTEL-MARVELL CONFIDENTIAL
***
*** LEAD SILICON QUAL VEHICLE
***
-------------- ----- -------- ------- -------------------- ---------------- ------------------- -------
STRESS RISK # LOTS UNITS/ PTQ GOAL PDQ REQUIREMENT FLQ REQUIREMENT NOTES
TOTAL LOT
-------------- ----- -------- ------- -------------------- ---------------- ------------------- -------
*** *** *** *** *** *** *** ***
-------------- ----- -------- ------- -------------------- ---------------- ------------------- -------
*** *** *** *** *** *** *** ***
-------------- ----- -------- ------- -------------------- ---------------- ------------------- -------
*** *** *** *** *** *** *** ***
-------------- ----- -------- ------- -------------------- ---------------- ------------------- -------
*** *** *** *** *** *** *** ***
-------------- ----- -------- ------- -------------------- ---------------- ------------------- -------
*** *** *** *** *** *** *** ***
-------------- ----- -------- ------- -------------------- ---------------- ------------------- -------
*** *** *** *** *** *** *** ***
-------------- ----- -------- ------- -------------------- ---------------- ------------------- -------
*** *** *** *** *** *** *** ***
-------------- ----- -------- ------- -------------------- ---------------- ------------------- -------
*** *** *** *** *** *** *** ***
-------------- ----- -------- ------- -------------------- ---------------- ------------------- -------
*** *** *** *** *** *** *** ***
-------------- ----- -------- ------- -------------------- ---------------- ------------------- -------
*** *** *** *** *** *** *** ***
-------------- ----- -------- ------- -------------------- ---------------- ------------------- -------
*** *** *** *** *** *** *** ***
-------------- ----- -------- ------- -------------------- ---------------- ------------------- -------
***
INTEL CORPORATION MARVELL SEMICONDUCTOR, INC.
By: _______________________________ By:___________________________________
Printed Name: _____________________ Printed Name: ________________________
Title: ____________________________ Title: _______________________________
Date: _____________________________ Date: ________________________________
-------------
*** The confidential portions of this agreement omitted pursuant to a
confidential treatment request filed separately with the Securities and
Exchange Commission and are indicated by the symbol "***".
15
47
INTEL-MARVELL CONFIDENTIAL
VER: V1.0
***
--------------------------------------------------------------------------------
1.0 INCORPORATION INTO AGREEMENT
The parties agree that this *** shall be attached to and incorporated into the
Agreement as *** to Exhibit C thereof. The purpose of this *** is to set forth
the terms and conditions under which Marvell shall develop the ***
Any changes to the specifications of the *** Product that are set forth in this
*** must be agreed to by the parties in writing.
2.0 DEFINITIONS AND PRODUCT DESCRIPTION
***
3.0 PRICING
3.1 ***
3.1.1 ***
---------- -------- ---------- ---------- --------- --------- ---------- --------
*** *** *** *** *** *** *** ***
---------- -------- ---------- ---------- --------- --------- ---------- --------
*** *** *** *** *** *** *** ***
---------- -------- ---------- ---------- --------- --------- ---------- --------
3.1.2 ***
4.0 STATEMENT OF WORK -- PROJECT DELIVERABLES AND SCHEDULE
4.1 PURPOSE
***
4.2 DEFINITIONS
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
-------------
*** The confidential portions of this agreement omitted pursuant to a
confidential treatment request filed separately with the Securities and
Exchange Commission and are indicated by the symbol "***".
1
48
INTEL-MARVELL CONFIDENTIAL
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
-------------
*** "The confidential portions of this agreement omitted pursuant to a
confidential treatment request filed separately with the Securities and
Exchange Commission and are indicated by the symbol "***"."
2
49
INTEL-MARVELL CONFIDENTIAL
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
*** ***
----------------------- ---------------------------------------------------------------
5.0 PROJECT MANAGEMENT
The parties agree to each assign dedicated Project Managers and Engineering
Managers to this project. The Intel Project Manager will have overall project
responsibility.
***
------------- ----------------- ---------------- ---------------- ------------------------
*** *** *** *** ***
------------- ----------------- ---------------- ---------------- ------------------------
*** *** *** *** ***
------------- ----------------- ---------------- ---------------- ------------------------
*** *** *** *** ***
------------- ----------------- ---------------- ---------------- ------------------------
*** *** *** *** ***
------------- ----------------- ---------------- ---------------- ------------------------
*** *** *** *** ***
------------- ----------------- ---------------- ---------------- ------------------------
In addition, when applicable, both parties agree to assign cross-functional team
members to the *** development project. These members will include employees of
each party representing, but not limited to, the following functions or
disciplines:
***
6.0 PRODUCT REQUIREMENTS AND SPECIFICATIONS
The following documents describe the *** product requirements and are
incorporated herein.
***
7.0 STATEMENT OF WORK ("SOW") -- PROJECT DELIVERABLES AND SCHEDULE;
RESTRICTION ON USE AND DISCLOSURE OF PARTIES' INTELLECTUAL PROPERTY
***
8.0 NRE AND QA CONFORMANCE COSTS PAYMENT SCHEDULES
***
-------------
*** The confidential portions of this agreement omitted pursuant to a
confidential treatment request filed separately with the Securities and
Exchange Commission and are indicated by the symbol "***".
3
50
INTEL-MARVELL CONFIDENTIAL
SCHEDULE PS4-A
------------------------------------------------ -------------- --------------
*** *** ***
------------------------------------------------ -------------- --------------
*** *** ***
------------------------------------------------ -------------- --------------
*** *** ***
------------------------------------------------ -------------- --------------
*** *** ***
------------------------------------------------ -------------- --------------
***
9.0 ***
9.1 ***
***
------------------------------- -------
*** ***
------------------------------- -------
*** ***
------------------------------- -------
*** ***
------------------------------- -------
*** ***
------------------------------- -------
*** ***
------------------------------- -------
***
***
***
***
-------------
*** "The confidential portions of this agreement omitted pursuant to a
confidential treatment request filed separately with the Securities and
Exchange Commission and are indicated by the symbol "***"."
4
51
INTEL-MARVELL CONFIDENTIAL
10.0 DESIGNATED PROJECT MANAGERS AND TECHNICAL POINTS OF CONTACT
For Marvell: For Intel:
***
INTEL CORPORATION MARVELL SEMICONDUCTOR, INC.
By: _________________________________ By:_________________________________
Printed Name: _______________________ Printed Name: ______________________
Title: ______________________________ Title: _____________________________
Date: _______________________________ Date: ______________________________
-------------
*** "The confidential portions of this agreement omitted pursuant to a
confidential treatment request filed separately with the Securities and
Exchange Commission and are indicated by the symbol "***"."
5
52
INTEL-MARVELL CONFIDENTIAL
***
REQUIRED FEATURES OF ***
*** PRODUCT REQUIREMENTS
***
***
INTEL CORPORATION MARVELL SEMICONDUCTOR, INC.
By: _________________________________ By:_________________________________
Printed Name: _______________________ Printed Name: ______________________
Title: ______________________________ Title: _____________________________
Date: _______________________________ Date: ______________________________
-------------
*** The confidential portions of this agreement omitted pursuant to a
confidential treatment request filed separately with the Securities and
Exchange Commission and are indicated by the symbol "***".
6
53
INTEL-MARVELL CONFIDENTIAL
***
***
PART I: ***
***
***
***
INTEL CORPORATION MARVELL SEMICONDUCTOR, INC.
By: _________________________________ By:_________________________________
Printed Name: _______________________ Printed Name: ______________________
Title: ______________________________ Title: _____________________________
Date: _______________________________ Date: ______________________________
-------------
*** The confidential portions of this agreement omitted pursuant to a
confidential treatment request filed separately with the Securities and
Exchange Commission and are indicated by the symbol "***".
7
54
INTEL-MARVELL CONFIDENTIAL
***
***
STATEMENT OF WORK ("SOW")
PHASE I: ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
MS TARGET TARGET ACTIVITY/DELIVERABLE BY/ TO
START END BETWEEN
MONTH MONTH
& YEAR & YEAR
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
PHASE II: ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
MS TARGET TARGET ACTIVITY/DELIVERABLE BY/ TO
START END BETWEEN
MONTH MONTH
& YEAR & YEAR
----------- ------- --------- ------------------------------------------------------ ------------ ---------
*** *** *** *** *** ***
---------- --------- ---------- ------------------------------------------------------ ------------- --------
*** *** *** *** *** ***
---------- --------- ---------- ------------------------------------------------------ ------------- --------
*** *** *** *** *** ***
---------- --------- ---------- ------------------------------------------------------ ------------- --------
*** *** *** *** *** ***
---------- --------- ---------- ------------------------------------------------------ ------------- --------
*** *** *** *** *** ***
---------- --------- ---------- ------------------------------------------------------ ------------- --------
PHASE III: ***
----------- ------- --------- ------------------------------------------------------ ------------ ---------
MS TARGET TARGET ACTIVITY/DELIVERABLE BY/ TO
START END BETWEEN
MONTH MONTH
& YEAR & YEAR
----------- ------- --------- ------------------------------------------------------ ------------ ---------
-------------
*** The confidential portions of this agreement omitted pursuant to a
confidential treatment request filed separately with the Securities and
Exchange Commission and are indicated by the symbol "***".
8
55
INTEL-MARVELL CONFIDENTIAL
--------- --------- -------- ------------------------------------------------------- ------------- ---------
*** *** *** *** *** ***
--------- --------- -------- ------------------------------------------------------- ------------- ---------
*** *** *** *** *** ***
--------- --------- -------- ------------------------------------------------------- ------------- ---------
*** *** *** *** *** ***
--------- --------- -------- ------------------------------------------------------- ------------- ---------
*** *** *** *** *** ***
--------- --------- -------- ------------------------------------------------------- ------------- ---------
*** *** *** *** *** ***
--------- --------- -------- ------------------------------------------------------- ------------- ---------
*** *** *** *** *** ***
--------- --------- -------- ------------------------------------------------------- ------------- ---------
*** *** *** *** *** ***
--------- --------- -------- ------------------------------------------------------- ------------- ---------
INTEL CORPORATION MARVELL SEMICONDUCTOR, INC.
By: ________________________________ By:__________________________________
Printed Name: ______________________ Printed Name: _______________________
Title: _____________________________ Title: ______________________________
Date: ______________________________ Date: _______________________________
-------------
*** "The confidential portions of this agreement omitted pursuant to a
confidential treatment request filed separately with the Securities and
Exchange Commission and are indicated by the symbol "***"."
9
56
INTEL-MARVELL CONFIDENTIAL
***
***
ACCEPTANCE CRITERIA
***
PHASE I
------------------- -----------------------------------------------------------------------
SOW MS ACCEPTANCE CRITERIA
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
PHASE II
------------------- -----------------------------------------------------------------------
SOW MS ACCEPTANCE CRITERIA
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
PHASE III
------------------- -----------------------------------------------------------------------
CORRESPONDING SOW ACCEPTANCE CRITERIA
MS
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
*** ***
------------------- -----------------------------------------------------------------------
INTEL CORPORATION MARVELL SEMICONDUCTOR, INC.
By: ________________________________ By:__________________________________
-------------
*** The confidential portions of this agreement omitted pursuant to a
confidential treatment request filed separately with the Securities and
Exchange Commission and are indicated by the symbol "***".
10
57
INTEL-MARVELL CONFIDENTIAL
Printed Name: _____________________ Printed Name: ________________________
Title: ____________________________ Title: _______________________________
Date: _____________________________ Date: ________________________________
▇▇
▇▇
▇▇▇▇▇-▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇▇
***
***
*** SILICON QUAL VEHICLE
PRELIMINARY Q&R REQUIREMENTS
***
-------------- ----- -------- ------- -------------------- ---------------- ------------------- -------
STRESS RISK # LOTS UNITS/ PTQ GOAL PDQ REQUIREMENT FLQ REQUIREMENT NOTES
TOTAL LOT
-------------- ----- -------- ------- -------------------- ---------------- ------------------- -------
*** *** *** *** *** *** *** ***
-------------- ----- -------- ------- -------------------- ---------------- ------------------- -------
*** *** *** *** *** *** *** ***
-------------- ----- -------- ------- -------------------- ---------------- ------------------- -------
*** *** *** *** *** *** *** ***
-------------- ----- -------- ------- -------------------- ---------------- ------------------- -------
*** *** *** *** *** *** *** ***
-------------- ----- -------- ------- -------------------- ---------------- ------------------- -------
*** *** *** *** *** *** *** ***
-------------- ----- -------- ------- -------------------- ---------------- ------------------- -------
*** *** *** *** *** *** *** ***
-------------- ----- -------- ------- -------------------- ---------------- ------------------- -------
*** *** *** *** *** *** *** ***
-------------- ----- -------- ------- -------------------- ---------------- ------------------- -------
*** *** *** *** *** *** *** ***
-------------- ----- -------- ------- -------------------- ---------------- ------------------- -------
*** *** *** *** *** *** *** ***
-------------- ----- -------- ------- -------------------- ---------------- ------------------- -------
*** *** *** *** *** *** *** ***
-------------- ----- -------- ------- -------------------- ---------------- ------------------- -------
*** *** *** *** *** *** *** ***
-------------- ----- -------- ------- -------------------- ---------------- ------------------- -------
***
INTEL CORPORATION MARVELL SEMICONDUCTOR, INC.
By: ________________________________ By:__________________________________
Printed Name: ______________________ Printed Name: _______________________
Title: _____________________________ Title: ______________________________
Date: ______________________________ Date: _______________________________
-------------
*** The confidential portions of this agreement omitted pursuant to a
confidential treatment request filed separately with the Securities and
Exchange Commission and are indicated by the symbol "***".
12